The Role of ATR Inhibitors in Ovarian Cancer : Investigating Predictive Biomarkers of Response
Ataxia telangiectasia and Rad-3 related kinase (ATR) signals DNA lesions and replication stress (RS) to the S and G2/M checkpoints and DNA repair pathways making it a promising target to exploit the dysregulated DNA damage response in cancer. ATR inhibitors (ATRi) are under clinical investigation as monotherapy and in combination with other anticancer agents. Molecular determinants of sensitivity to ATRi are common in ovarian cancer, suggesting the therapeutic potential of ATRi. We investigated the cytotoxicity of the ATRi, VE-821, in a panel of human ovarian cancer cell lines. High grade serous (HGS) cell lines were significantly more sensitive to VE-821 than non-HGS (p ≤ 0.0001) but previously identified determinants of sensitivity (TP53, ATM and BRCA1) were not predictive. Only low RAD51 (p = 0.041), TopBP1 (p = 0.026) and APOBEC3B (p = 0.015) protein expression were associated with increased VE-821 sensitivity. HGS cells had increased levels of RS (pRPASer4/8 and γH2AX nuclear immunofluorescence), and elevated RS predicted sensitivity to VE-821 independently of the cell line subtype. These data suggest that functional assessment of RS biomarkers may be a better predictive biomarker of ATRi response than any single aberrant gene in ovarian cancer and potentially other cancers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Cells - 11(2022), 15 vom: 01. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bradbury, Alice [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.08.2022 Date Revised 23.11.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/cells11152361 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34473000X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34473000X | ||
| 003 | DE-627 | ||
| 005 | 20231226023445.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cells11152361 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1149.xml |
| 035 | |a (DE-627)NLM34473000X | ||
| 035 | |a (NLM)35954206 | ||
| 035 | |a (PII)2361 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bradbury, Alice |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Role of ATR Inhibitors in Ovarian Cancer |b Investigating Predictive Biomarkers of Response |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.08.2022 | ||
| 500 | |a Date Revised 23.11.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Ataxia telangiectasia and Rad-3 related kinase (ATR) signals DNA lesions and replication stress (RS) to the S and G2/M checkpoints and DNA repair pathways making it a promising target to exploit the dysregulated DNA damage response in cancer. ATR inhibitors (ATRi) are under clinical investigation as monotherapy and in combination with other anticancer agents. Molecular determinants of sensitivity to ATRi are common in ovarian cancer, suggesting the therapeutic potential of ATRi. We investigated the cytotoxicity of the ATRi, VE-821, in a panel of human ovarian cancer cell lines. High grade serous (HGS) cell lines were significantly more sensitive to VE-821 than non-HGS (p ≤ 0.0001) but previously identified determinants of sensitivity (TP53, ATM and BRCA1) were not predictive. Only low RAD51 (p = 0.041), TopBP1 (p = 0.026) and APOBEC3B (p = 0.015) protein expression were associated with increased VE-821 sensitivity. HGS cells had increased levels of RS (pRPASer4/8 and γH2AX nuclear immunofluorescence), and elevated RS predicted sensitivity to VE-821 independently of the cell line subtype. These data suggest that functional assessment of RS biomarkers may be a better predictive biomarker of ATRi response than any single aberrant gene in ovarian cancer and potentially other cancers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ATR inhibitor | |
| 650 | 4 | |a VE-821 | |
| 650 | 4 | |a monotherapy | |
| 650 | 4 | |a ovarian cancer | |
| 650 | 4 | |a replication stress | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Minor Histocompatibility Antigens |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a ATR protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Ataxia Telangiectasia Mutated Proteins |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a APOBEC3B protein, human |2 NLM | |
| 650 | 7 | |a EC 3.5.4.5 |2 NLM | |
| 650 | 7 | |a Cytidine Deaminase |2 NLM | |
| 650 | 7 | |a EC 3.5.4.5 |2 NLM | |
| 700 | 1 | |a Zenke, Frank T |e verfasserin |4 aut | |
| 700 | 1 | |a Curtin, Nicola J |e verfasserin |4 aut | |
| 700 | 1 | |a Drew, Yvette |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cells |d 2011 |g 11(2022), 15 vom: 01. Aug. |w (DE-627)NLM227066421 |x 2073-4409 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:15 |g day:01 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cells11152361 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 15 |b 01 |c 08 | ||